MANTICORE 101 - Breast: A Trial to Prevent Heart Issues in Breast Cancer Patients
Author Information
Author(s): Pituskin Edith, Haykowsky Mark, Mackey John R, Thompson Richard B, Ezekowitz Justin, Koshman Sheri, Oudit Gavin, Chow Kelvin, Pagano Joseph J, Paterson Ian
Primary Institution: University of Alberta
Hypothesis
Can conventional heart failure pharmacotherapy prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer?
Conclusion
The MANTICORE trial aims to provide important evidence on the effectiveness of heart failure medications in preventing heart issues caused by trastuzumab in breast cancer patients.
Supporting Evidence
- Trastuzumab has been shown to improve survival in HER2+ breast cancer patients.
- Cardiac toxicity from cancer therapies is a significant health issue.
- Conventional heart failure medications have been effective in other settings.
Takeaway
This study is trying to find out if heart medications can help prevent heart problems in women with a specific type of breast cancer who are getting treatment.
Methodology
A parallel 3-arm, randomized, placebo-controlled, double-blind design with 159 patients receiving either an ACE inhibitor, a beta-blocker, or a placebo for one year.
Potential Biases
Potential biases related to participant selection and the double-blind nature of the study.
Limitations
The study may not find significant decreases in cardiac outcomes due to the small sample size.
Participant Demographics
Patients with histologically confirmed HER2+ early breast cancer, aged over 18 years.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website